Pierre Eftekhari, J Clin Toxicol 2016, 6:6(Suppl)
http://dx.doi.org/10.4172/2161-0495.C1.021

7th Euro-Global Summit on
Toxicology & Applied Pharmacology
October 24-26, 2016 Rome, Italy

Individualised clinical toxicology: Physiological intermolecular modulation spectroscopy (PIMS), a technology to forsee drugs efficacy prior to administration

Pierre Eftekhari
Inoviem Scientific, France

Toxicology today is in need of new insight. In air of individualised medicine the relation between desired clinical effect and toxic or side-effects should be considered simultaneously. Genomics, proteomics, metabolomics and omics in general, although extremely valuable, are globally lacking clinical relevance. Therefore, there is a need for new methodologies and new tools enabling us to make a bridge between predicted omics-based drug toxicity and clinics. Here, I shall present Physiological Intermolecular Modulation Spectroscopy (PIMS) a cutting edge techology meant to stratify the patients as responders or non-responders in regard to a pharmacological active agent. PIMS provides individual fingerprints based on drug-induced macromolecular modulation directly on human tissue extracts. I will explain the scientific background of PIMS and present the results from two different clinical studies (transversal and longitudinal), using peripheral blood mononuclear cells (PBMC) isolated from patients with ulcerative colitis and Crohn's disease for the prediction of infliximab effect.

Biography

Pierre Eftekhari has completed his PhD from Strasbourg University. He has more than 19 years of experience in Drug Development and is the President of Inoviem Scientific, a company dedicated to cutting edge solutions in drug development. He has published more than 30 papers in reputed journals and filed several patents.

p.eftekhari@inoviem.com

Notes: